JAVIER
CORTES CASTAN
PROFESOR
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital General Universitario Gregorio Marañón (16)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
-
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
Annals of Oncology, Vol. 35, Núm. 7, pp. 630-642
-
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 2060-2069
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998
2019
2018
-
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826
-
Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia
-
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)
Clinical and Translational Oncology
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2009
-
Prognostic and predictive factors and genetic analysis of early breast cancer
Clinical and Translational Oncology
2006
-
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation
International Journal of Radiation Oncology Biology Physics, Vol. 64, Núm. 4, pp. 1122-1128
2005
-
Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer
International Journal of Radiation Oncology Biology Physics, Vol. 61, Núm. 5, pp. 1378-1384
2002
-
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer
British Journal of Cancer, Vol. 87, Núm. 2, pp. 158-160